Cyanopyridine as a privileged scaffold in drug discovery
Authors:
- Yingjie ChangYCYingjie Chang
- Xuben HouXHXuben Hou
- Hao FangHFHao Fang
- 4 August 2023
- book chapter
- Published by Elsevier
- p. 163-198
Abstract
No abstract availableThis publication has 117 references indexed in Scilit:
- PKC-θ function at the immunological synapse: prospects for therapeutic targetingTrends in Immunology, 2011
- Synthesis, antitumor and antimicrobial activities of 4-(4-chlorophenyl)-3-cyano-2-(β-O-glycosyloxy)-6-(thien-2-yl)-nicotinonitrileEuropean Journal of Medicinal Chemistry, 2011
- Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory applicationBioorganic & Medicinal Chemistry Letters, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemiaBioorganic & Medicinal Chemistry Letters, 2009
- Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCθ inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Reduction of a Redox-Active Ligand Drives Switching in a Cu(I) Pseudorotaxane by a Bimolecular MechanismJournal of the American Chemical Society, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Synthesis and transformations of 6-amino-3,5-dicyano-4ethylpyridine-2(1H)-thioneChemistry of Heterocyclic Compounds, 1996